The mission of Crescendo Bioscience, Inc. is to enable more effective management of autoimmune and inflammatory diseases by providing quantitative, objective molecular tests and disease information services to rheumatologists and patients.
Crescendo Bioscience concentrates its efforts in rheumatology and is currently focused on rheumatoid arthritis (RA), a debilitating, chronic disease affecting over 1.5 million people in the United States and more than 2 million in Europe. Although there is no known cure for RA, multiple therapies are available, with widely differing levels of effectiveness and significant potential toxicities. Choosing the optimal treatment from among these therapeutic alternatives is a tremendous challenge.
At Crescendo, we are committed to improving rheumatologists’ ability to understand the biology underlying RA and to better determine the status of a patient’s disease. We work closely with collaborators from leading academic medical institutions and continue building long-term relationships with clinicians. Vectra® DA is the first and only multi-biomarker blood test validated to measure RA disease activity. Vectra DA integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score to help physicians make more informed treatment decisions. Vectra DA testing is performed at our specialized, CLIA (Clinical Laboratory Improvement Amendments) facility and test results are reported to the physician 7 to 10 days following receipt of the blood sample.
As part of our commitment to providing disease information services, Crescendo developed MyRA™, a free mobile app for people living with RA which was designed to empower patients to regularly track multiple aspects of their RA and easily share the information with their physician. MyRA was developed with the input of both patients and healthcare providers and has received high praise for its ability to track multiple aspects (e.g. medications, morning stiffness, joint pain,daily functionality, etc.) of RA and integrate those into a summary report that can be easily shared with physicians. MyRA even allows patients to customize and track the issues they care about most. Patients can share a summary report of tracked data with their physician, enabling them to more effectively communicate how they are doing, which enables the physician to better treat and manage their patient’s RA.
Crescendo Bioscience is a privately held company that is funded by Kleiner Perkins Caufield & Byers, Mohr Davidow, aeris CAPITAL AG, Skyline Ventures, Safeguard Scientifics, and other investors. Crescendo Bioscience entered into a strategic investment agreement with Myriad Genetics, Inc.